Elanco Animal Health has introduced Pradalex™ (pradofloxacin injection), the first new injectable antibiotic approved by the FDA in nearly two decades for treating bovine respiratory disease (BRD). BRD, also known as shipping fever, is one of the most costly diseases in the cattle industry, leading to significant health challenges and economic losses.
Key Features of Pradalex:
- Single-dose, low-volume treatment for BRD in beef cattle.
- Fast-acting—reaching high plasma concentrations within 45 minutes.
- Broad-spectrum efficacy, targeting key BRD pathogens, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
- Industry-leading withdrawal period, supporting responsible antibiotic use.
Pradalex offers a new mode of action to help producers and veterinarians combat BRD effectively, reinforcing Elanco’s commitment to innovative animal health solutions.
For more details, visit: Pradalex for Cattle
